{"id":673132,"date":"2026-03-31T15:02:14","date_gmt":"2026-03-31T07:02:14","guid":{"rendered":"https:\/\/law.asia\/?p=673132"},"modified":"2026-04-02T11:34:53","modified_gmt":"2026-04-02T03:34:53","slug":"otsuka-pharmaceutical-biotech-acquisition-skadden","status":"publish","type":"post","link":"https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/","title":{"rendered":"\u30b9\u30ad\u30e3\u30c7\u30f3\u3001\u5927\u585a\u88fd\u85ac\u306b\u3088\u308b\u6700\u5927US$1.2 billion\u898f\u6a21\u306e\u30d0\u30a4\u30aa\u30c6\u30c3\u30af\u8cb7\u53ce\u306e\u53ef\u80fd\u6027\u306b\u3064\u3044\u3066\u52a9\u8a00"},"content":{"rendered":"<p style=\"text-align: justify;\">\u6771\u4eac\u306b\u672c\u793e\u3092\u7f6e\u304f\u5927\u585a\u88fd\u85ac\u304c\u81e8\u5e8a\u6bb5\u968e\u306e\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u3067\u3042\u308bTranscend Therapeutics\u3092\u8cb7\u53ce\u3059\u308b\u53d6\u5f15\u306b\u3064\u3044\u3066\u3001Skadden, Arps, Slate, Meagher &amp; Flom\uff08\u4ee5\u4e0b\u30b9\u30ad\u30e3\u30c7\u30f3\uff09\u306f\u6cd5\u7684\u30a2\u30c9\u30d0\u30a4\u30b9\u3092\u3057\u3066\u3044\u308b\u3053\u3068\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u672c\u53d6\u5f15\u306e\u4fa1\u5024\u306f\u6700\u5927\u3067US$1.2 billion\u3068\u306a\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002<\/p>\n<p style=\"text-align: justify;\">\u30b9\u30ad\u30e3\u30c7\u30f3\u306e\u30c1\u30fc\u30e0\u306b\u306f\u3001\u6771\u4eac\u62e0\u70b9\u306e\u30d1\u30fc\u30c8\u30ca\u30fc\u3067\u3042\u308b\u795e\u8c37\u5149\u5f18\u6c0f\u3001\u30d1\u30ed\u30a2\u30eb\u30c8\u62e0\u70b9\u306e\u30d1\u30fc\u30c8\u30ca\u30fc\u3067\u3042\u308bMike Mies\u6c0f\u3001\u30a2\u30b8\u30a2\u592a\u5e73\u6d0b\u5730\u57df\u62c5\u5f53\u306e\u30ab\u30a6\u30f3\u30bb\u30eb\u3067\u3042\u308bLouis Artime\u6c0f\u304c\u53c2\u52a0\u3057\u307e\u3057\u305f\u3002\u30e2\u30eb\u30ac\u30f3\u30fb\u30b9\u30bf\u30f3\u30ec\u30fc\u304c\u5927\u585a\u88fd\u85ac\u306b\u8ca1\u52d9\u52a9\u8a00\u3092\u304a\u3053\u306a\u3044\u307e\u3057\u305f\u3002<\/p>\n<p style=\"text-align: justify;\">\u5408\u610f\u6761\u4ef6\u306b\u3088\u308c\u3070\u3001\u5927\u585a\u88fd\u85ac\u306f\u53d6\u5f15\u5b8c\u4e86\u5f8c\u306bTranscend\u306e\u682a\u4e3b\u306b7\u5104\u30c9\u30eb\u3092\u652f\u6255\u3044\u307e\u3059\u3002\u53d6\u5f15\u5b8c\u4e86\u306f2026\u5e74\u7b2c2\u56db\u534a\u671f\u306b\u898b\u8fbc\u307e\u308c\u3066\u3044\u307e\u3059\u3002\u3055\u3089\u306b\u3001\u5927\u585a\u88fd\u85ac\u306f\u958b\u767a\u4e2d\u8cc7\u7523\u306b\u95a2\u9023\u3059\u308b\u5c06\u6765\u306e\u58f2\u4e0a\u30de\u30a4\u30eb\u30b9\u30c8\u30fc\u30f3\u306b\u57fa\u3065\u304d\u3001\u8ffd\u52a0\u306e\u5076\u767a\u5bfe\u4fa1\u3068\u3057\u3066\u6700\u59275.25\u5104\u30c9\u30eb\u3092\u652f\u6255\u3046\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002<\/p>\n<p style=\"text-align: justify;\">Kirkland &amp; Ellis\u306f\u3001\u30d1\u30fc\u30c8\u30ca\u30fc\u306eGraham Robinson\u6c0f\u304a\u3088\u3073Laura Knoll\u6c0f\u304c\u4e3b\u5c0e\u3057\u3001Pillsbury Winthrop Shaw Pittman\u306e\u30d1\u30fc\u30c8\u30ca\u30fc\u3067\u3042\u308bRon Fleming Jr\u6c0f\u3068\u3068\u3082\u306b\u3001\u30cb\u30e5\u30fc\u30e8\u30fc\u30af\u62e0\u70b9\u306eTranscend\u306e\u30ab\u30a6\u30f3\u30bb\u30eb\u3092\u52d9\u3081\u307e\u3057\u305f\u3002<\/p>\n<p style=\"text-align: justify;\">Centerview Partners\u306fTranscend\u306b\u8ca1\u52d9\u52a9\u8a00\u3092\u304a\u3053\u306a\u3044\u3001\u30d1\u30fc\u30c8\u30ca\u30fc\u306eAndrew S. Rymer\u6c0f\u304a\u3088\u3073Jason Zuckerbrod\u6c0f\u3001\u30d7\u30ea\u30f3\u30b7\u30d1\u30eb\u306eTommaso Verderame\u6c0f\u3067\u69cb\u6210\u3055\u308c\u308b\u30c1\u30fc\u30e0\u304c\u62c5\u5f53\u3057\u307e\u3057\u305f\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u6771\u4eac\u306b\u672c\u793e\u3092\u7f6e\u304f\u5927\u585a\u88fd\u85ac\u304c\u81e8\u5e8a\u6bb5\u968e\u306e\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u3067\u3042\u308bTranscend Therapeutics\u3092\u8cb7\u53ce\u3059\u308b\u53d6\u5f15\u306b\u3064\u3044\u3066\u3001Skadden, Arps, Slate, Meagher &amp; Flom\uff08\u4ee5\u4e0b\u30b9<\/p>\n","protected":false},"author":13501,"featured_media":672755,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"sfsi_plus_gutenberg_text_before_share":"","sfsi_plus_gutenberg_show_text_before_share":"","sfsi_plus_gutenberg_icon_type":"","sfsi_plus_gutenberg_icon_alignemt":"","sfsi_plus_gutenburg_max_per_row":"","meta-author":""},"categories":[8404,8529],"tags":[180727,114964,17954,180728,163388,151087,162525,186540,151473,186539,112147,148031,127822,124592],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v17.7 (Yoast SEO v17.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<meta name=\"description\" content=\"\u6771\u4eac\u306b\u672c\u793e\u3092\u7f6e\u304f\u5927\u585a\u88fd\u85ac\u304c\u81e8\u5e8a\u6bb5\u968e\u306e\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u3067\u3042\u308bTranscend Therapeutics\u3092\u8cb7\u53ce\u3059\u308b\u53d6\u5f15\u306b\u3064\u3044\u3066\u3001Skadden, Arps, Slate, Meagher &amp; Flom\uff08\u4ee5\u4e0b\u30b9\u30ad\u30e3\u30c7\u30f3\uff09\u306f\u6cd5\u7684\u30a2\u30c9\u30d0\u30a4\u30b9\u3092\u3057\u3066\u3044\u308b\u3053\u3068\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u672c\u53d6\u5f15\u306e\u4fa1\u5024\u306f\u6700\u5927\u3067US$1.2 billion\u3068\u306a\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u30b9\u30ad\u30e3\u30c7\u30f3\u3001\u5927\u585a\u88fd\u85ac\u306b\u3088\u308b\u6700\u5927US$1.2 billion\u898f\u6a21\u306e\u30d0\u30a4\u30aa\u30c6\u30c3\u30af\u8cb7\u53ce\u306e\u53ef\u80fd\u6027\u306b\u3064\u3044\u3066\u52a9\u8a00\" \/>\n<meta property=\"og:description\" content=\"\u6771\u4eac\u306b\u672c\u793e\u3092\u7f6e\u304f\u5927\u585a\u88fd\u85ac\u304c\u81e8\u5e8a\u6bb5\u968e\u306e\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u3067\u3042\u308bTranscend Therapeutics\u3092\u8cb7\u53ce\u3059\u308b\u53d6\u5f15\u306b\u3064\u3044\u3066\u3001Skadden, Arps, Slate, Meagher &amp; Flom\uff08\u4ee5\u4e0b\u30b9\u30ad\u30e3\u30c7\u30f3\uff09\u306f\u6cd5\u7684\u30a2\u30c9\u30d0\u30a4\u30b9\u3092\u3057\u3066\u3044\u308b\u3053\u3068\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u672c\u53d6\u5f15\u306e\u4fa1\u5024\u306f\u6700\u5927\u3067US$1.2 billion\u3068\u306a\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/\" \/>\n<meta property=\"og:site_name\" content=\"Law.asia\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/AsiaBusinessLaw\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-31T07:02:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-02T03:34:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/law.asia\/wp-content\/uploads\/2026\/03\/Skadden-advises-Otsuka-on-potential-USD1.2bn-biotech-buy.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ablj_insights\" \/>\n<meta name=\"twitter:site\" content=\"@ablj_insights\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Website team 05\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Organization\",\"@id\":\"https:\/\/law.asia\/ja\/#organization\",\"name\":\"Law.asia\",\"url\":\"https:\/\/law.asia\/ja\/\",\"sameAs\":[\"https:\/\/www.facebook.com\/AsiaBusinessLaw\/\",\"https:\/\/www.instagram.com\/law.asia_\/?hl=en\",\"https:\/\/www.linkedin.com\/company\/asiabusinesslawjournal\/\",\"https:\/\/www.youtube.com\/@Law.asiaLimited\",\"https:\/\/twitter.com\/ablj_insights\"],\"logo\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/law.asia\/ja\/#logo\",\"inLanguage\":\"ja\",\"url\":\"https:\/\/law.asia\/wp-content\/uploads\/2020\/10\/LAWDOTASIA-LOGO-152.png\",\"contentUrl\":\"https:\/\/law.asia\/wp-content\/uploads\/2020\/10\/LAWDOTASIA-LOGO-152.png\",\"width\":152,\"height\":152,\"caption\":\"Law.asia\"},\"image\":{\"@id\":\"https:\/\/law.asia\/ja\/#logo\"}},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/law.asia\/ja\/#website\",\"url\":\"https:\/\/law.asia\/ja\/\",\"name\":\"Law.asia\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/law.asia\/ja\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/law.asia\/ja\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ja\"},{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/#primaryimage\",\"inLanguage\":\"ja\",\"url\":\"https:\/\/law.asia\/wp-content\/uploads\/2026\/03\/Skadden-advises-Otsuka-on-potential-USD1.2bn-biotech-buy.jpg\",\"contentUrl\":\"https:\/\/law.asia\/wp-content\/uploads\/2026\/03\/Skadden-advises-Otsuka-on-potential-USD1.2bn-biotech-buy.jpg\",\"width\":900,\"height\":600,\"caption\":\"Otsuka Pharmaceutical Biotech Acquisition\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/#webpage\",\"url\":\"https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/\",\"name\":\"\\u30b9\\u30ad\\u30e3\\u30c7\\u30f3\\u3001\\u5927\\u585a\\u88fd\\u85ac\\u306b\\u3088\\u308b\\u6700\\u5927US$1.2 billion\\u898f\\u6a21\\u306e\\u30d0\\u30a4\\u30aa\\u30c6\\u30c3\\u30af\\u8cb7\\u53ce\\u306e\\u53ef\\u80fd\\u6027\\u306b\\u3064\\u3044\\u3066\\u52a9\\u8a00 | Law.asia\",\"isPartOf\":{\"@id\":\"https:\/\/law.asia\/ja\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/#primaryimage\"},\"datePublished\":\"2026-03-31T07:02:14+00:00\",\"dateModified\":\"2026-04-02T03:34:53+00:00\",\"description\":\"\\u6771\\u4eac\\u306b\\u672c\\u793e\\u3092\\u7f6e\\u304f\\u5927\\u585a\\u88fd\\u85ac\\u304c\\u81e8\\u5e8a\\u6bb5\\u968e\\u306e\\u30d0\\u30a4\\u30aa\\u30c6\\u30af\\u30ce\\u30ed\\u30b8\\u30fc\\u4f01\\u696d\\u3067\\u3042\\u308bTranscend Therapeutics\\u3092\\u8cb7\\u53ce\\u3059\\u308b\\u53d6\\u5f15\\u306b\\u3064\\u3044\\u3066\\u3001Skadden, Arps, Slate, Meagher & Flom\\uff08\\u4ee5\\u4e0b\\u30b9\\u30ad\\u30e3\\u30c7\\u30f3\\uff09\\u306f\\u6cd5\\u7684\\u30a2\\u30c9\\u30d0\\u30a4\\u30b9\\u3092\\u3057\\u3066\\u3044\\u308b\\u3053\\u3068\\u3092\\u767a\\u8868\\u3057\\u307e\\u3057\\u305f\\u3002\\u672c\\u53d6\\u5f15\\u306e\\u4fa1\\u5024\\u306f\\u6700\\u5927\\u3067US$1.2 billion\\u3068\\u306a\\u308b\\u53ef\\u80fd\\u6027\\u304c\\u3042\\u308a\\u307e\\u3059\\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\"}]},{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/#webpage\"},\"author\":{\"@id\":\"https:\/\/law.asia\/ja\/#\/schema\/person\/1eb0eca4569d71fa927502833bd61d4b\"},\"headline\":\"\\u30b9\\u30ad\\u30e3\\u30c7\\u30f3\\u3001\\u5927\\u585a\\u88fd\\u85ac\\u306b\\u3088\\u308b\\u6700\\u5927US$1.2 billion\\u898f\\u6a21\\u306e\\u30d0\\u30a4\\u30aa\\u30c6\\u30c3\\u30af\\u8cb7\\u53ce\\u306e\\u53ef\\u80fd\\u6027\\u306b\\u3064\\u3044\\u3066\\u52a9\\u8a00\",\"datePublished\":\"2026-03-31T07:02:14+00:00\",\"dateModified\":\"2026-04-02T03:34:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/#webpage\"},\"wordCount\":42,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/law.asia\/ja\/#organization\"},\"image\":{\"@id\":\"https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/law.asia\/wp-content\/uploads\/2026\/03\/Skadden-advises-Otsuka-on-potential-USD1.2bn-biotech-buy.jpg\",\"keywords\":[\"Corporate law\",\"IPO\",\"M&amp;A\",\"Mergers and acquisitions\",\"Pillsbury Winthrop Shaw Pittman\",\"\\u30af\\u30ed\\u30b9\\u30dc\\u30fc\\u30c0\\u30fcM&amp;A\",\"\\u30d0\\u30a4\\u30aa\\u30c6\\u30af\\u30ce\\u30ed\\u30b8\\u30fc\",\"\\u30d8\\u30eb\\u30b9\\u30b1\\u30a2\\u6848\\u4ef6\",\"\\u30e9\\u30a4\\u30d5\\u30b5\\u30a4\\u30a8\\u30f3\\u30b9\",\"\\u6226\\u7565\\u7684\\u8cb7\\u53ce\",\"\\u65e5\\u672c\",\"\\u6cd5\\u5f8b\\u4e8b\\u52d9\\u6240\",\"\\u7c73\\u56fd\",\"\\u88fd\\u85ac\\u696d\\u754c\"],\"articleSection\":[\"Asia Business Law Journal\",\"\\u696d\\u754c\\u30cb\\u30e5\\u30fc\\u30b9\"],\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\/\/law.asia\/#organization\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/law.asia\/ja\/#\/schema\/person\/1eb0eca4569d71fa927502833bd61d4b\",\"name\":\"Website team 05\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/law.asia\/ja\/#personlogo\",\"inLanguage\":\"ja\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9aabbf305ce0ba4ee191f1c8271609b1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9aabbf305ce0ba4ee191f1c8271609b1?s=96&d=mm&r=g\",\"caption\":\"Website team 05\"},\"url\":\"https:\/\/law.asia\/ja\/author\/johnmanson\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"description":"\u6771\u4eac\u306b\u672c\u793e\u3092\u7f6e\u304f\u5927\u585a\u88fd\u85ac\u304c\u81e8\u5e8a\u6bb5\u968e\u306e\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u3067\u3042\u308bTranscend Therapeutics\u3092\u8cb7\u53ce\u3059\u308b\u53d6\u5f15\u306b\u3064\u3044\u3066\u3001Skadden, Arps, Slate, Meagher & Flom\uff08\u4ee5\u4e0b\u30b9\u30ad\u30e3\u30c7\u30f3\uff09\u306f\u6cd5\u7684\u30a2\u30c9\u30d0\u30a4\u30b9\u3092\u3057\u3066\u3044\u308b\u3053\u3068\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u672c\u53d6\u5f15\u306e\u4fa1\u5024\u306f\u6700\u5927\u3067US$1.2 billion\u3068\u306a\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/","og_locale":"ja_JP","og_type":"article","og_title":"\u30b9\u30ad\u30e3\u30c7\u30f3\u3001\u5927\u585a\u88fd\u85ac\u306b\u3088\u308b\u6700\u5927US$1.2 billion\u898f\u6a21\u306e\u30d0\u30a4\u30aa\u30c6\u30c3\u30af\u8cb7\u53ce\u306e\u53ef\u80fd\u6027\u306b\u3064\u3044\u3066\u52a9\u8a00","og_description":"\u6771\u4eac\u306b\u672c\u793e\u3092\u7f6e\u304f\u5927\u585a\u88fd\u85ac\u304c\u81e8\u5e8a\u6bb5\u968e\u306e\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u3067\u3042\u308bTranscend Therapeutics\u3092\u8cb7\u53ce\u3059\u308b\u53d6\u5f15\u306b\u3064\u3044\u3066\u3001Skadden, Arps, Slate, Meagher & Flom\uff08\u4ee5\u4e0b\u30b9\u30ad\u30e3\u30c7\u30f3\uff09\u306f\u6cd5\u7684\u30a2\u30c9\u30d0\u30a4\u30b9\u3092\u3057\u3066\u3044\u308b\u3053\u3068\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u672c\u53d6\u5f15\u306e\u4fa1\u5024\u306f\u6700\u5927\u3067US$1.2 billion\u3068\u306a\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002","og_url":"https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/","og_site_name":"Law.asia","article_publisher":"https:\/\/www.facebook.com\/AsiaBusinessLaw\/","article_published_time":"2026-03-31T07:02:14+00:00","article_modified_time":"2026-04-02T03:34:53+00:00","og_image":[{"width":900,"height":600,"url":"https:\/\/law.asia\/wp-content\/uploads\/2026\/03\/Skadden-advises-Otsuka-on-potential-USD1.2bn-biotech-buy.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_creator":"@ablj_insights","twitter_site":"@ablj_insights","twitter_misc":{"\u57f7\u7b46\u8005":"Website team 05","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"1\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Organization","@id":"https:\/\/law.asia\/ja\/#organization","name":"Law.asia","url":"https:\/\/law.asia\/ja\/","sameAs":["https:\/\/www.facebook.com\/AsiaBusinessLaw\/","https:\/\/www.instagram.com\/law.asia_\/?hl=en","https:\/\/www.linkedin.com\/company\/asiabusinesslawjournal\/","https:\/\/www.youtube.com\/@Law.asiaLimited","https:\/\/twitter.com\/ablj_insights"],"logo":{"@type":"ImageObject","@id":"https:\/\/law.asia\/ja\/#logo","inLanguage":"ja","url":"https:\/\/law.asia\/wp-content\/uploads\/2020\/10\/LAWDOTASIA-LOGO-152.png","contentUrl":"https:\/\/law.asia\/wp-content\/uploads\/2020\/10\/LAWDOTASIA-LOGO-152.png","width":152,"height":152,"caption":"Law.asia"},"image":{"@id":"https:\/\/law.asia\/ja\/#logo"}},{"@type":"WebSite","@id":"https:\/\/law.asia\/ja\/#website","url":"https:\/\/law.asia\/ja\/","name":"Law.asia","description":"","publisher":{"@id":"https:\/\/law.asia\/ja\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/law.asia\/ja\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ja"},{"@type":"ImageObject","@id":"https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/#primaryimage","inLanguage":"ja","url":"https:\/\/law.asia\/wp-content\/uploads\/2026\/03\/Skadden-advises-Otsuka-on-potential-USD1.2bn-biotech-buy.jpg","contentUrl":"https:\/\/law.asia\/wp-content\/uploads\/2026\/03\/Skadden-advises-Otsuka-on-potential-USD1.2bn-biotech-buy.jpg","width":900,"height":600,"caption":"Otsuka Pharmaceutical Biotech Acquisition"},{"@type":"WebPage","@id":"https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/#webpage","url":"https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/","name":"\u30b9\u30ad\u30e3\u30c7\u30f3\u3001\u5927\u585a\u88fd\u85ac\u306b\u3088\u308b\u6700\u5927US$1.2 billion\u898f\u6a21\u306e\u30d0\u30a4\u30aa\u30c6\u30c3\u30af\u8cb7\u53ce\u306e\u53ef\u80fd\u6027\u306b\u3064\u3044\u3066\u52a9\u8a00 | Law.asia","isPartOf":{"@id":"https:\/\/law.asia\/ja\/#website"},"primaryImageOfPage":{"@id":"https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/#primaryimage"},"datePublished":"2026-03-31T07:02:14+00:00","dateModified":"2026-04-02T03:34:53+00:00","description":"\u6771\u4eac\u306b\u672c\u793e\u3092\u7f6e\u304f\u5927\u585a\u88fd\u85ac\u304c\u81e8\u5e8a\u6bb5\u968e\u306e\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u3067\u3042\u308bTranscend Therapeutics\u3092\u8cb7\u53ce\u3059\u308b\u53d6\u5f15\u306b\u3064\u3044\u3066\u3001Skadden, Arps, Slate, Meagher & Flom\uff08\u4ee5\u4e0b\u30b9\u30ad\u30e3\u30c7\u30f3\uff09\u306f\u6cd5\u7684\u30a2\u30c9\u30d0\u30a4\u30b9\u3092\u3057\u3066\u3044\u308b\u3053\u3068\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u672c\u53d6\u5f15\u306e\u4fa1\u5024\u306f\u6700\u5927\u3067US$1.2 billion\u3068\u306a\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002","breadcrumb":{"@id":"https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home"}]},{"@type":"NewsArticle","@id":"https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/#article","isPartOf":{"@id":"https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/#webpage"},"author":{"@id":"https:\/\/law.asia\/ja\/#\/schema\/person\/1eb0eca4569d71fa927502833bd61d4b"},"headline":"\u30b9\u30ad\u30e3\u30c7\u30f3\u3001\u5927\u585a\u88fd\u85ac\u306b\u3088\u308b\u6700\u5927US$1.2 billion\u898f\u6a21\u306e\u30d0\u30a4\u30aa\u30c6\u30c3\u30af\u8cb7\u53ce\u306e\u53ef\u80fd\u6027\u306b\u3064\u3044\u3066\u52a9\u8a00","datePublished":"2026-03-31T07:02:14+00:00","dateModified":"2026-04-02T03:34:53+00:00","mainEntityOfPage":{"@id":"https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/#webpage"},"wordCount":42,"commentCount":0,"publisher":{"@id":"https:\/\/law.asia\/ja\/#organization"},"image":{"@id":"https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/#primaryimage"},"thumbnailUrl":"https:\/\/law.asia\/wp-content\/uploads\/2026\/03\/Skadden-advises-Otsuka-on-potential-USD1.2bn-biotech-buy.jpg","keywords":["Corporate law","IPO","M&amp;A","Mergers and acquisitions","Pillsbury Winthrop Shaw Pittman","\u30af\u30ed\u30b9\u30dc\u30fc\u30c0\u30fcM&amp;A","\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc","\u30d8\u30eb\u30b9\u30b1\u30a2\u6848\u4ef6","\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9","\u6226\u7565\u7684\u8cb7\u53ce","\u65e5\u672c","\u6cd5\u5f8b\u4e8b\u52d9\u6240","\u7c73\u56fd","\u88fd\u85ac\u696d\u754c"],"articleSection":["Asia Business Law Journal","\u696d\u754c\u30cb\u30e5\u30fc\u30b9"],"inLanguage":"ja","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/law.asia\/ja\/otsuka-pharmaceutical-biotech-acquisition-skadden\/#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/law.asia\/#organization"}},{"@type":"Person","@id":"https:\/\/law.asia\/ja\/#\/schema\/person\/1eb0eca4569d71fa927502833bd61d4b","name":"Website team 05","image":{"@type":"ImageObject","@id":"https:\/\/law.asia\/ja\/#personlogo","inLanguage":"ja","url":"https:\/\/secure.gravatar.com\/avatar\/9aabbf305ce0ba4ee191f1c8271609b1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9aabbf305ce0ba4ee191f1c8271609b1?s=96&d=mm&r=g","caption":"Website team 05"},"url":"https:\/\/law.asia\/ja\/author\/johnmanson\/"}]}},"_links":{"self":[{"href":"https:\/\/law.asia\/ja\/wp-json\/wp\/v2\/posts\/673132"}],"collection":[{"href":"https:\/\/law.asia\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/law.asia\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/law.asia\/ja\/wp-json\/wp\/v2\/users\/13501"}],"replies":[{"embeddable":true,"href":"https:\/\/law.asia\/ja\/wp-json\/wp\/v2\/comments?post=673132"}],"version-history":[{"count":2,"href":"https:\/\/law.asia\/ja\/wp-json\/wp\/v2\/posts\/673132\/revisions"}],"predecessor-version":[{"id":673288,"href":"https:\/\/law.asia\/ja\/wp-json\/wp\/v2\/posts\/673132\/revisions\/673288"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/law.asia\/ja\/wp-json\/wp\/v2\/media\/672755"}],"wp:attachment":[{"href":"https:\/\/law.asia\/ja\/wp-json\/wp\/v2\/media?parent=673132"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/law.asia\/ja\/wp-json\/wp\/v2\/categories?post=673132"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/law.asia\/ja\/wp-json\/wp\/v2\/tags?post=673132"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}